Objective: To evaluate the effects of topical propranolol for treatment of the corneal neovascularization (CNV) in a rabbit model of corneal injury. Methods: The CNV model was induced by 3 sutures of the cornea in 20 rabbits (20 corneas). 2 weeks after CNV, all sutures were removed then rabbits were divided randomly into two groups: Groups 1 received topical propranolol 10 mg/mL and Group 2 received only topical normal saline drops as control group, in the right eyes three times a day for 2 weeks. Photographs of (CNV) were obtained before drug administration and at 1 and 2 weeks after therapy. The images were analyzed using NIH Image J1.49c software.
INTRODUCTION
C orneal neovascularization (CNV) is a common consequence of various inflammatory, infectious, and traumatic corneal disorders. [1] Neovascularization (NV) induces tissue scarring, lipid deposition, stromal hemorrhage, and corneal edema, all of which severely affect visual acuity. [2] In addition, vascularity reduces the immune privilege of the cornea and the likelihood of graft survival in patients who subsequently elect to undergo penetrating keratoplasty. [3] Angiogenesis is mediated by several different factors, including vascular endothelial growth factor (VEGF) and platelet-derived growth factor. VEGF is a homodimeric glycoprotein, heparin-binding growth factor specific to vascular endothelial cells commonly considered the most prominent angiogenic factor. Within the VEGF family, VEGF-A is considered to be the major factor involved in hemangiogenesis and has received the most attention as the mediator of pathologic NV.2-5 VEGF and its tyrosine kinase receptors, VEGF receptor 1 (VEGF1), and VEGFR2, promote many aspects of the angiogenic process. [4] [5] [6] [7] [8] [9] Propranolol is a nonselective beta-adrenergic receptor blocker drug. Several studies have reported betaadrenergic system is one of the major stimulating factors that increase VEGF production. Hence, beta-blockers can reduce VEGF production and subsequently regression of NV. [10, 11] Propranolol has no effect on the normal level of VEGF that its mechanism remained largely unknown. [11] Recent studies have shown propranolol can reduce VEGF production in oxygen-induced retinopathy. [11] [12] [13] Currently, there is no evidence of propranolol effect on CNV except only one study in 2014 that reported a non-significant effect. [10] ORIGINAL ARTICLE Therefore, the present study was aimed to investigate the anti-angiogenic effects of topical administration propranolol in experimentally-induced CNV in a rabbit model.
MATERIALS AND METHODS
In this study, 20 wild brown male rabbits, weighing 1500-1900 g, were used. The protocol for this experimental study was approved by the Institutional Animal Care and Use Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Animal maintenance and all in vivo experiments were performed in accordance with the institutional guidelines and the Association for Research in Vision and Ophthalmology Statement.
The animals were anesthetized by IM injections of tiletamine (2.5 mg/kg body weight), zolazepam (2.5 mg/kg), and xylazine (3.45 mg/kg) if needed. After the application of topical tetracaine, three 7-0 silk sutures were placed radially, at mid-stromal depth, at the 10, 12, and 2 O'clock positions on the corneas of the right eyes, avoiding corneal perforation. Topical ciprofloxacin was instilled twice a day to minimize the risk of infection after surgery. Corneal sutures were removed 2 weeks after suture placement. After suture removal, the 20 rabbits were divided into two groups, with 10 rabbits in each group. In Groups 1 and 2, the right eyes received topical applications of propranolol (10 mg/mL) and saline, respectively. The solutions were administered three times a day for 2 weeks, starting immediately after suture removal. The concentrations of topical Propranolol were chosen from previous studies. [10, 12] All treated and control eyes were photographed using a chargecoupled device camera attached to a slit-lamp biomicroscope at ×40 magnification. Photographs were obtained before drug administration and at 1 and 2 weeks after therapy.
The images were analyzed using NIH image J1.49 software. The resolution of each image was 640 × 480 pixels. All images were converted to tagged information file format files. The quantification of NV throughout the entire cornea was performed in a blinded fashion to minimize sampling bias. The area of corneal vasculature was outlined with the computer mouse and calculated using the Image J software. To control for individual variation in the area of NV induced by the suture, the area before anti-neovascular treatment was set at 100%, and post-treatment area values were presented as the percentage of the remaining NV. This approach for measurement is consistent with the previously described method. [14] [15] [16] [17] [18] [19] [20] [21] Statistical analyses were performed using SPSS version 21.0 for Windows. The Mann-Whitney U-test was used for comparisons between administrations of two drugs. Differences were considered statistically significant when P values were <0.05.
RESULTS
Biomicroscopic examination of the rabbits' eyes at 1 and 2 weeks after the initiation of treatment revealed that CNV in eyes that received propranolol had regressed more than those received saline [ Figure 1 ].
The mean percentage of CNV area estimated as 100% before treatment. At the 1 week after treatment, the mean percentage of NV area in propranolol and saline group were 78.01 ± 4.16 and 93.33 ± 4.57, respectively. In addition, at the 2 weeks after treatment were 65.72 ± 4.15 and 84.96 ± 5.21, respectively [ Table 1 ].
After 1 week treatment, the NV area in propranolol group was regressed more than saline group significantly (P < 0.0001).
After 2 weeks treatment, the NV area in propranolol group was regressed more than saline group significantly (P < 0.0001) [ Figure 2 ]. Figure 3 showed the changes of CNV area in 2 weeks treatment.
The mean percentage of changes of CNV area in propranolol and saline groups were 34.28 ± 4.15 and 15.04 ± 5.21, respectively [ Table 2 ]. The mean percentage of regression of CNV area in propranolol group was different to saline group significantly (P < 0.0001).
DISCUSSION
The treatment of CNV can be challenging and problematic. [4] [5] [6] [7] [8] Various anti-angiogenic therapy strategies have been used to interfere with the VEGF system. At present, the clinical focus in the treatment of CNV involves the use of antibodies to VEGF. [9] Hashemian et al. in 2011 and Öner et al. in 2012 have reported a non-significant difference statistically between topical and subconjunctival bevacizumab for CNV in an experimental rat model but both of them were effective. [15, 16] In our study, topical propranolol has been evaluated and it was effective. Kim et al. in 2013 have shown topically administered bevacizumab had longer standing anti-angiogenic effect than subconjunctivally injected bevacizumab in rat CNV. They reported observations of epitheliopathy and corneal thinning after topical bevacizumab. These adverse effects generally appeared during the 2 nd month of treatment. On the contrary, in the current study, no instance of epitheliopathy or corneal thinning by topical propranolol was observed. This may be because the study lasted for only 2 weeks, which may be too short a period to allow for the development of epitheliopathy. [17] Simavli et al. in 2014 have shown topical propranolol has no significant inhibitory effect on CNV statistically. [10] While our study shows topical propranolol can inhibit CNV statistically.
Padrini et al. in 2014 studied pharmacokinetics and local safety profile of propranolol eye drops in rabbits and reported retinal concentration of propranolol is similar in topically and orally administration. [22] Ristori et al. in 2011 studied the role of the adrenergic system in a mouse model of oxygen-induced retinopathy and antiangiogenic effects of beta-adrenoreceptor blockade. They reported betareceptor blockade is protective against retinal angiogenesis by reducing VEGF but no effect on normal level of VEGF. [11] The results of our experiments demonstrated that regression of CNV area in topical propranolol group was different to saline group significantly, 2.28-fold after 2 weeks.
Several studies have shown that propranolol can reduce VEGF and VEGFR1 and VEGFR2 production and also shown inhibition by propranolol of VEGF-induced tyrosine phosphorylation of VEGFR2 lead to inhibition of downstream signaling such as the activation of the extracellular signalregulated kinase-1/2 and the secretion of the extracellular matrix degrading enzyme matrix metalloproteinase-2. Taken together, these results demonstrate that propranolol interferes with several essential steps of NV and opens up novel therapeutic opportunities for the use of β-blockers in the treatment of angiogenesis-dependent human diseases. However, its mechanism of action is as yet unknown totally.
CONCLUSION
Our findings strengthen the hypothesis that β-AR blockade can efficiently counteract NV and show topical propranolol can regress CNV in short term period and suggest propranolol as an alternative drug to bevacizumab because it is available and cost-benefit.
Our study suggests that topical eye application of propranolol can represent an alternative delivery route to systemic administration thus avoiding the risk of associated complications and side effects that could make this drug unsafe in long-term treatment.
However, the evaluation of multiple doses of topical propranolol and the efficacy and side effects of long-term treatment for CNV needs more investigations. The limitations of our study include the short follow-up period and the lack of information about the biocompatibility of topical propranolol. Further, trials with longer periods of follow-up will be necessary. Further, studies of the optimal dosage, treatment interval, and duration are also recommended.
